MaxCyte, Inc. MaxCyte Joins the Alliance for mRNA Medicines
16 Novembro 2023 - 10:05AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
16 November 2023
MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a
Founding Member
MaxCyte continues supporting the advancement of novel
therapeutics and looks to support education and advancement of mRNA
medicines.
ROCKVILLE, MD , November 16, 2023 - MaxCyte, Inc. , (Nasdaq:
MXCT; LSE: MXCT), a leading, cell-engineering focused company
providing enabling platform technologies to advance the discovery,
development and commercialization of next-generation cell-based
therapeutics and innovative bioprocessing applications, today
announced that it has joined the Alliance for mRNA Medicines ( AMM
), as a founding member. AMM is the leading global organization
dedicated to advancing and advocating for mRNA and next-generation
encoding RNA therapeutics and vaccines for the benefit of patients,
public health and society. AMM's mission is to propel the future of
mRNA medicines, improve patients' lives, and advance scientific
knowledge by convening and empowering mRNA industry leaders,
innovators, scientists and other key stakeholders. MaxCyte is one
of 31 founding members comprised of biotechnology, biopharma and
life sciences companies and educational institutions.
"We proudly join our colleagues in advancing AMM's mission as we
recognize the significant potential of mRNA scientific innovation
to transform human health," said Doug Doerfler, President and CEO
of MaxCyte. "Our versatile, leading electroporation platform
continues to provide scientific innovators with a powerful and
flexible transfection method to accelerate the development of
critical medicines and vaccines. We remain steadfast in our
commitment to enable development of new applications for mRNA
technology."
The AMM was launched in early November at the 11th International
mRNA Health Conference in Berlin, Germany. AMM and the
organization's advisors will advocate for policies that encourage
innovation and funding, define regulatory and reimbursement
standards, support manufacturing, and promote access to mRNA
medicines to patients by educating and engaging with governments,
policymakers, regulators and other stakeholders in North America,
Europe and Asia Pacific.
"We look forward to collaborating with AMM and its members to
advance and advocate for the adoption of mRNA and next-generation
encoding RNA therapeutics and vaccines for the prevention,
treatment and cure of human disease," added Mr. Doerfler.
"Supporting the efforts of AMM aligns perfectly with our on-going
efforts to provide efficient, scalable, and best-in-class
electroporation technology, afforded by our unparalleled industry
expertise, to enable our partners' advancement at the frontiers of
mRNA medicines."
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize
the potential of cells to improve patients' lives. We have spent
more than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today's processes to innovate tomorrow's
solutions. Our ExPERT(TM) platform, which is based on our Flow
Electroporation (R) technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx(TM), STx(TM), GTx(TM)
and VLx (TM); a portfolio of proprietary related processing
assemblies or disposables; and software protocols, all supported by
a robust worldwide intellectual property portfolio. By providing
our partners with the right technology platform, as well as
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on X (formerly Twitter) and LinkedIn .
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
valerie@spectrumscience.com
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAGPGCUGUPWGUQ
(END) Dow Jones Newswires
November 16, 2023 08:05 ET (13:05 GMT)
Maxcyte (LSE:MXCT)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Maxcyte (LSE:MXCT)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024